ArticleCureus2025
The Impact of Type 2 Diabetes Mellitus on the Severity of Alzheimer's Disease in Hispanic Populations in the Rio Grande Valley: A Pilot Retrospective Chart Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Recruiting People With Dementia in Emergency Research: Insights From Geriatric Emergency Care Applied Research 2.0 Network (GEAR 2.0) Pilot Studies.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAlzheimer's disease (AD) is becoming more prevalent worldwide, leading to a growing demand to understand the impact of risk factors on disease progression. Notably, type 2 diabetes mellitus (DM) has emerged as a significant risk factor for the development of AD, given the pathophysiological role of insulin resistance in cognitive impairment. In particular, the impact of type 2 DM on AD development and severity may be heightened in Hispanic populations due to the high prevalence of both conditions in this community. Here, we sought to understand the role of type 2 DM in AD severity in a Hispanic population from the Rio Grande Valley (RGV), a community wherein 91% of the population identifies as Hispanic.
methodsWe conducted a pilot retrospective chart review from January 2018 to March 2024 at UTHealth RGV for patients with AD who self-identified as Hispanic, Mexican, or Latino. Medical charts were evaluated for a diagnosis of type 2 DM, and demographics were recorded. We categorized the included charts into two groups: AD with DM and AD without DM. For all charts, the Global Deterioration Scale (GDS) score was manually determined from the electronic medical record. T-tests were used to evaluate differences between the two groups.
resultsForty patients met the inclusion criteria for our study. Eleven medical charts were excluded (72.5% analysis rate) due to insufficient documentation for GDS scoring. No significant differences were found in baseline demographics between the AD with DM and AD without DM groups. GDS scores were not statistically different between groups (p = 0.152), although a medium effect size was observed (d = 0.52, 95% CI (-0.18, 1.23)), with higher GDS scores in the AD with DM group.
conclusionOur findings suggest a trend toward more severe AD in Hispanic patients with type 2 DM. Based on these results, we recommend the development of standardized assessment tools for AD, particularly for use in small community clinics, to improve the evaluation of disease progression. Improved clinical documentation and assessment may help identify risk factors that allow for earlier diagnosis or preventive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.